Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma

INTRODUCTION: Benralizumab, an interleukin-5 receptor alpha–directed cytolytic anti-eosinophil monoclonal antibody, was recently approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma with eosinophilic inflammation. METHODS: Pharmacokinetic (PK) data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Li, Wang, Bing, Chia, Yen Lin, Roskos, Lorin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584252/
https://www.ncbi.nlm.nih.gov/pubmed/30854591
http://dx.doi.org/10.1007/s40262-019-00738-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584252/
https://www.ncbi.nlm.nih.gov/pubmed/30854591
http://dx.doi.org/10.1007/s40262-019-00738-4

Ejemplares similares